5 Pharma stocks in which FIIs bought stake in Q1 FY26 to look out for5 Pharma stocks in which FIIs bought stake in Q1 FY26 to look out for

Introduction

Foreign Institutional Investors (FIIs) are entities from outside India that invest in Indian stocks. Their buying activity often reflects confidence in a company’s prospects and can impact stock prices.

In Q1 FY26, FIIs increased their stakes in five pharma stocks. This shows growing foreign interest in the pharmaceutical sector. Here are five pharma companies where FIIs boosted their holdings recently.

Also Read: Electric equipment stock hits 20% upper circuit after its net profits grow by 512.5% YoY

Ind-Swift Laboratories

On August 14, 2025, Ind-Swift Laboratories Ltd opened at ₹107.95, up 2.77% from its previous close of ₹105.05. The stock reached a high of ₹107.95 and a low of ₹102.50. By 4:01 PM, it traded at ₹102.50, a 2.43% decrease, with a market cap of ₹621.34 crore.

In Q1 FY26, FIIs acquired a 13.61% stake in Ind-Swift Laboratories, signaling strong foreign institutional interest in the company.

Ind-Swift Laboratories Ltd (NSE: INDSWFTLAB), founded in 1995, manufactures APIs and formulations for regulated global markets, specializing in cardiovascular, antidiabetic, antipsychotic, and antibiotic therapies with strong research and development capabilities.

Aarti Drugs

On August 14, 2025, Aarti Drugs Ltd (AARTIDRUGS) opened at ₹497.95, down 0.59% from its previous close of ₹488.15. The stock reached a high of ₹497.95 and a low of ₹482.75. By 4:00 PM, it traded at ₹485.25, with a market cap of ₹4,428.88 crore.

In Q1 FY26, FIIs increased their stake in Aarti Drugs by 0.01%, indicating modest foreign institutional investment in the company.

Aarti Drugs Ltd (NSE: AARTIDRUGS), established in 1984, manufactures and exports APIs, pharma intermediates, specialty chemicals, and formulations to over 100 countries as part of the $1000 million Aarti Group.

Amrutanjan Health Care

On August 14, 2025, Amrutanjan Health Care Ltd (AMRUTANJAN) opened at ₹676.50, down 0.61% from its previous close of ₹681.85. The stock reached a high of ₹697.50 and a low of ₹668.55. By 4:00 PM, it traded at ₹686.00, with a market cap of ₹2,005.22 crore.

In Q1 FY26, FIIs bought a 0.11% stake in Amrutanjan Health Care, showing slight foreign institutional interest in the company.

Amrutanjan Health Care Ltd (NSE: AMRUTANJAN) has been producing ayurvedic pain relief balms since 1893. It also offers OTC products in women’s hygiene and packaged fruit juice segments. Managed by third-generation promoters.

Also Read: Transformer stock hits 5% upper circuit after reporting 224% YoY increase in net profits

Alembic Pharmaceuticals

On August 14, 2025, Alembic Pharmaceuticals Ltd (APLLTD) opened at ₹943.60, up 1.81% from its previous close of ₹943.60. The stock reached a high of ₹978.00 and a low of ₹942.20. By 4:00 PM, it traded at ₹960.65, with a market cap of ₹18,882.84 crore.

In Q1 FY26, FIIs acquired a 0.02% stake in Alembic Pharma, reflecting modest foreign institutional buying activity in the company.

Alembic Pharmaceuticals Ltd (NSE: APLLTD) develops, manufactures, and markets pharmaceutical formulations and active ingredients. The company operates three R&D centers and five manufacturing facilities, focusing on innovation and quality in healthcare products.

Astrazeneca Pharma

On August 14, 2025, AstraZeneca Pharma India Ltd (ASTRAZEN) opened at ₹8,459.10, up 0.32% from its previous close of ₹8,417.20. The stock reached a high of ₹8,987.40 and a low of ₹8,210.00. By 4:00 PM, it traded at ₹8,443.90, with a market cap of ₹21,109.75 crore.

In Q1 FY26, FIIs increased their stake in AstraZeneca Pharma by 0.14%, indicating growing foreign institutional interest in the company.

Astrazeneca Pharma India Ltd (NSE: ASTRAZEN) manufactures, distributes, and markets pharmaceutical products. Promoted by AstraZeneca UK, it holds a diverse portfolio and contributed to the Oxford-AstraZeneca COVID-19 vaccine development.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs